Latest News
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
12 September 2025 - Gene Solutions, a company involved in mitochondrial dysfunction genomics and CNS drug discovery, announced on Thursday the publication of its platform technology patent.The award covers novel technologies underpinning the company&...
Zentiva announces sale from Advent to GTCR
12 September 2025 - Generics pharmaceutical company Zentiva, together with private equity investors Advent and GTCR, on Thursday announced the sale of Zentiva by Advent to GTCR.Since acquiring Zentiva from Sanofi in 2018, Advent has worked closely wi...
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
12 September 2025 - Chinese biopharmaceutical company Shanghai Zhimeng Biopharma Inc announced on Thursday that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, has recently received clinical trial approval from th...
Avidity Biosciences prices upsized common stock public offering
12 September 2025 - Avidity Biosciences Inc (Nasdaq:RNA), a US biopharmaceutical focused on delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), announced on Thursday the pricing of its upsized underwritten pu...
EMA validates Daiichi Sankyo's ENHERTU type II variation application for HER2 positive metastatic solid tumours
11 September 2025 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) said on Thursday that the European Medicines Agency (EMA) has validated the Type II Variation marketing authorisation application for ENHERTU (trastuzumab deruxtecan) fo...